Why the study?
Does chemotherapy improve survival and response rates in adults with soft tissue sarcomas?
Does chemotherapy improve survival and response rates in adults with soft tissue sarcomas?
Single-agent doxorubicin remains the standard first-line chemotherapy for advanced adult soft tissue sarcomas, while adjuvant chemotherapy offers a small survival benefit.
Answers are grounded in this paper and cite their sources.
Supports doxorubicin as first-line; confirms modest adjuvant benefit yet leaves optimal regimens open.
Adult soft tissue sarcomas are relatively rare tumours which are curable with radical surgery. Approximately 50% of patients will develop inoperable disease or metastases for which chemotherapy may be appropriate. Only two cytotoxic agents - doxorubicin and ifosfamide - have activity in >20% of patients. For both these agents there is evidence of a dose-response relationship. There is currently no good evidence that combination chemotherapy confers a clinical benefit compared with single agents. Outside a clinical trial, standard first-line therapy should be with single agent doxorubicin at a dose intensity >/=70 mg2 every 3 weeks. Approximately 25% of patients may be expected to respond to this regimen. There is the suggestion that responses may occur to ifosfamide in patients who progress on doxorubicin. The role of chemotherapy in the adjuvant setting remains uncertain. Several trials have suggested a modest relapse-free and overall survival benefit for the use of post-operative chemotherapy and a recent overview of 14 randomised trials confirms a small though significant benefit. These benefits have to be weighed against the toxicity of chemotherapy. The importance of treating all patients with soft tissue sarcomas in clinical trials is stressed. There is an urgent need to define new active agents to treat this disease.
No takes yet. Share an insight, caveat, or question.
O’Byrne et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: